Get the Stockscreener App
28.08
1.12%
0.31
After Hours:
28.02
-0.06
-0.21%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $28.08, with a volume of 44.76M.
It is up +1.12% in the last 24 hours and up +1.56% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$27.77
Open:
$27.99
24h Volume:
44.76M
Relative Volume:
1.01
Market Cap:
$159.73B
Revenue:
$62.58B
Net Income/Loss:
$7.79B
P/E Ratio:
20.72
EPS:
1.3551
Net Cash Flow:
$9.08B
1W Performance:
+4.15%
1M Performance:
+1.56%
6M Performance:
+10.20%
1Y Performance:
+10.81%
1-Day Range:
$27.79
$28.31
1-Week Range:
$27.02
$28.31
52-Week Range:
$20.91
$28.31
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
28.08 | 157.97B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
919.77 | 792.08B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.44 | 584.06B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
217.49 | 376.96B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
197.22 | 300.68B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.29 | 291.99B | 64.93B | 18.26B | 12.36B | 7.2751 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit - Bloomberg Law News
Pfizer to close South San Francisco research site (PFE:NYSE) - Seeking Alpha
Pfizer Inc. (NYSE:PFE) Tracks Healthcare Allocation In S&P 500 fund - Kalkine Media
Moderna, Pfizer Press to Toss Bayer’s Covid-Shot Patent Suits - Bloomberg Law News
Exclusive: Pfizer to shutter South S.F. research site, end Bay Area presence - San Francisco Chronicle
Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation - TechStock²
Pfizer Inc Stock (PFE) Moved Up by 3.06% on Mar 31: Facts Behind the Movement - TradingKey
Pfizer Stock Edges Higher as Oncology Wins and Pipeline Bets Fuel Optimism Amid Flat 2026 Outlook - International Business Times Australia
Pfizer (NYSE:PFE) Hits New 1-Year HighWhat's Next? - MarketBeat
Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - Barchart
Pfizer stock hits 52-week high at 27.99 USD By Investing.com - Investing.com Australia
Pfizer stock hits 52-week high at 27.99 USD - Investing.com
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry - finance.yahoo.com
Pfizer Inc. $PFE Shares Purchased by QSM Asset Management Ltd - MarketBeat
Retirement Systems of Alabama Acquires 379,870 Shares of Pfizer Inc. $PFE - MarketBeat
U.S. Rivaroxaban Market Set to Boom Rapidly by 2033 | Pfizer Inc. • Merck & Co. • Amgen Inc - openPR.com
Mn Services Vermogensbeheer B.V. Boosts Position in Pfizer Inc. $PFE - MarketBeat
Is It Time To Reconsider Pfizer (PFE) After Diverging Valuation Narratives? - simplywall.st
Director at Pfizer (NYSE: PFE) receives phantom stock unit grant - Stock Titan
Pfizer (PFE) director Shantanu Narayen receives 1,849 Phantom Stock Units as deferred pay - Stock Titan
Pfizer (PFE) director Mortimer Buckley awarded 1,386.834 phantom units - Stock Titan
Pfizer says long-awaited Lyme vaccine was effective in study - UnionLeader.com
Pfizer (NYSE:PFE) Shares Up 2.6%Time to Buy? - MarketBeat
Pfizer's Post-2025 Strategy: Acquiring New GLP-1 Therapy After Internal SetbackNews and Statistics - IndexBox
Pharma Stocks Pfizer and GSK Provide Safe Investment Options Amid Market Uncertainty: Charts - Intellectia AI
Pfizer’s CAO on Building a Data and Process Foundation for AI - WSJ
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - finance.yahoo.com
Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass” - Insider Monkey
Travelers Vaccines Market Set to Boom Rapidly, Witnessing - openPR.com
Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline - Yahoo Finance Singapore
Esophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. Dominate - finance.yahoo.com
Pfizer Grant for Generic JAK Inhibitors in Rheumatology (USA) - fundsforNGOs
Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends - Insider Monkey
Comirnaty Vaccine: Pfizer's Cornerstone COVID-19 Product Continues to Shape Global Health Markets in - AD HOC NEWS
Prediction: Buying Pfizer Stock Today Could Set You Up for Life - The Globe and Mail
Prediction: Buying Pfizer Stock Today Could Set You Up for Life - The Motley Fool
Pfizer Developments Draw Attention Across Market Benchmarks - Kalkine Media
Advisors Management Group Inc. ADV Sells 39,525 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Pfizer Oncology Wins Raise Questions On Valuation Gap And Future Revenues - simplywall.st
Pfizer Inc. Trade Ideas — BSESOF:PFE - TradingView
Lyme disease vaccine 70 percent effective: Pfizer - FOX 8 News
Wedge Capital Management L L P NC Grows Position in Pfizer Inc. $PFE - MarketBeat
A New Lyme Disease Vaccine Is In the Works - Women's Health
PFE Stock Quote Price and Forecast - CNN
Exchange Traded Concepts LLC Sells 60,810 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer (NYSE:PFE) Trading Down 2%Here's Why - MarketBeat
PFEPfizer Inc Stock Price and Quote - Finviz
Pfizer Options Spot-On: On March 27th, 99,614 Contracts Were Traded, With 2.42 Million Open Interest - Moomoo
Pfizer Inc. stock underperforms Friday when compared to competitors - MarketWatch
Pfizer: Why Wall Street Habitually Overestimates Target Price (NYSE:PFE) - Seeking Alpha
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pfizer Inc Stock (PFE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
4.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):